| Website | argolynbioscience... |
| Category | BioTech |
| Phone | 919-806-4634 |
| Employees |
| TOTAL | $15.8M |
| VENTURE FUNDING TOTAL | $15.8M |
| Series A, 6/07 InterSouth Partners Quaker BioVentures Amgen Ventures | $15.8M |
Argolyn Bioscience is a privately held biopharmaceutical company dedicated to discovering and developing novel peptide drug candidates to treat psychosis, pain, and other serious diseases and disorders. Our most advanced development candidate is ABS201, a first-in-class peptide derivative currently in preclinical development for the treatment of schizophrenia. A second development candidate will soon enter preclinical development as a first-in-class analgesic. These, and other product candidates in our portfolio, were developed using our proprietary amino acid analog substitution technology which enables the rapid and efficient discovery of novel, peptide-based drug candidates.
